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Abstract— Transgenic pigs were generated that produced human 
protein C in their milk at up to 1 g/liter. The gene construct was a fu-
sion gene consisting of the cDNA for human protein C inserted into 
the fi rst exon of the mouse whey acidic protein gene. These results 
demonstrate that the mouse whey acidic protein gene contains regu-
latory elements that can direct cDNA expression at high levels in the 
pig mammary gland. Recombinant human protein C that was pro-
duced at about 380 pg/ml per hr in transgenic pig milk possessed an-
ticoagulant activity that was equivalent to that of protein C derived 
from human plasma. These studies provide evidence that γ-carboxyl-
ation can occur at high levels in the mammary gland of a pig.
Abbreviations: hPC, human protein C; rhPC, recombinant hPC; 
WAP, whey acidic protein; nt, nucleotide(s); APTT, activated partial 
thromboplastin time; NRPP, normal reference plasma pool. 
Several different regulatory sequences have been identifi edfor milk 
protein genes that enable the expression of heterologous proteins 
in the milk of transgenic animals (1–4). However, expression lev-
els from cDNAs (1, 4) and genomic sequences have been variable, 
with genomic sequences frequently producing much higher levels 
of protein (2, 3). For example, the cDNA encoding human factor IX 
(hFIX) was expressed in sheep milk at only 25 ng/ml using a fusion 
gene consisting of 4.0 kilobase pairs (kbp) of 5′ fl anking sequence 
from the sheep β-lactoglobulin gene (BLG), 1.5 kbp of hFIX cDNA, 
and 4.9 kbp containing the BLG transcription unit and 3′ fl anking se-
quence (1). In contrast, secretion of up to 30 mg/ml of human α1-an-
titrypsin (hAAT) into sheep milk was achieved using the same 4.0 
kbp of BLG 5′ fl anking sequence fused to 6.5 kbp of hAAT minigene 
(fi rst intron removed) coding sequence (3). Additionally, there is no 
direct correlation between the level of expression in transgenic mice 
compared to livestock for a given genetic construct (2, 4). For exam-
ple, transgenic pigs expressed a 7.2-kbp genomic fragment of mouse 
whey acidic protein (WAP) at a 2-to 100-fold greater level (2, 5) than 
transgenic mice with the same construct. Therefore, the choice of 
employing a cDNA versus a genomic construct to synthesize a given 
protein in the mammary gland of livestock can become complex.
Human protein C (hPC) is a regulator of hemostasis, suggesting 
its potential use as a therapy for many disease states (6). Protein C is 
a zymogen of a serine protease that is activated by thrombin (6). The 
structure of hPC is complex and its level of expression in recombi-
nant mammalian cells (7) and transgenic mice (8) has been limited to 
<1 μg/ml per hr. In this report, we detail the expression of functional 
recombinant hPC (rhPC) in the milk of transgenic swine at 1000 μg/
ml per hr using a hybrid genetic construct consisting of the cDNA of 
hPC regulated by the mouse WAP gene.
MATERIALS AND METHODS
Transgenic Swine. Crossbred gilts served as embryo donors 
and recipients of microinjected eggs. Estrus synchronization, surgi-
cal procedures, and pronuclear microinjection of centrifuged zygotes 
were performed as described by Wall et al.(9). About 1–3 pl of DNA 
solution (3.3 μg of DNA per ml in 10 mM Tris-HCl/0.25 mM EDTA, 
pH 7.4) was microinjected as described by Brinster et al. (10). The 
hybrid transgene (WAPPC-1) consists of the cDNA for hPC insert-
ed into the unique Kpn I site in the fi rst exon of the mouse WAP gene 
(11), as illustrated in Fig. 1.
Tail tissue was biopsied from 2-day-old piglets and DNA was 
isolated using a modifi cation of the procedure developed by Marmur 
(12). Transgenic founder animals were identifi ed initially by poly-
merase chain reaction (PCR) (13) using hPC-specifi c primers and 
later confi rmed by Southern analysis using 32P-labeled hPC cDNA.
Mammary gland biopsies were performed on two transgenic fe-
males and a control female on days 55 and 35 of lactation, respec-
tively. Biopsies were washed briefl y in sterile saline and immedi-
ately frozen in liquid nitrogen. Total RNA was isolated from the pig 
mammary gland biopsies and human liver tissue samples (14). RNA 
samples (10 μg) were fractionated using agarose/formaldehyde gels 
and then transferred by vacuum onto nylon membranes. The mem-
branes were probed with 32P random primer-labeled hPC cDNA or 
WAP cDNA.
Pig Milk Collection and Preparation. Piglets were removed 
from the sows for ≈ 30 min prior to milking to allow for milk ac-
cumulation. Milk letdown was induced by intramuscular administra-
tion of 20–30 international units of oxytocin. Milk was collected di-
rectly into Tris-buffered saline/EDTA buffer (2 × TBS/EDTA: 100 
mM Tris-HCl, 300 mM NaCl, 200 mM EDTA, pH 6.5, chilled to 0–2 
°C) in a 1:1 buffer to milk ratio. Fat and precipitate were removed by 
centrifugation at 15,000 × g for 20 min at 0–2 °C. The diluted whey 
was then fi ltered through sterile gauze to remove residual solids and 
stored at –90 °C. Control pig milk was treated identically.
Analysis of rhPC. Expression levels in the whey were deter-
mined by ELISA, using a monoclonal antibody (HPC4-Mab) that has 
a calcium-dependent binding epitope in the activation peptide (15). 
The rhPC captured by the HPC4-Mab was detected using horserad-
ish peroxidase conjugated to goat anti-rabbit IgG following a 3-hr in-
cubation at room temperature with a rabbit polyclonal antibody to 
hPC. A second ELISA procedure was also used in which rabbit poly-
clonal anti-hPC antiserum was used to immunocapture rhPC fol-
lowed by detection with a sandwich of goat anti-hPC antiserum and 
rabbit anti-goat antiserum conjugated to horse-radish peroxidase. 
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The rhPC from transgenic pig whey was purifi ed and fractionat-
ed by using three successive immunosorptions by HPC4-Mab immo-
bilized onto Affi -Prep 10 (BioRad). Briefl y, the whey was diluted to 
15 mg of total protein per ml and then loaded onto the column in the 
presence of 50 mM Ca2+ in TBS (pH 7.2) at 3-fold excess of column 
capacity assuming 0.2 mg of hPC antigen per ml of immunosorbent. 
The rhPC that was bound to the immunosorbent for each of three 
successive immunodepletions of the starting whey was specifi cally 
eluted with 50 mM EDTA in TBS (pH 7.2). The fall-through from 
the fi rst immunopurifi cation was applied to the same immunosorbent 
but at 10% of column capacity based upon antigen levels detected by 
polyclonal ELISA. The fall-through of the second immunopurifi ca-
tion was adjusted to pH 8.5 and applied to the HPC4-Mab immuno-
sorbent at 10% of column capacity based upon antigen levels detect-
ed by polyclonal ELISA. 
The biological activity of the rhPC was measured using an acti-
vated partial thromboplastin time (APTT) assay (16). The APTT re-
agent included Protac (Agkistrodon contortrix venom, American Di-
agnostics, Greenwich, CT) to specifi cally activate hPC or rhPC prior 
to adding CaCl2 to initiate coagulation. 
RESULTS
DNA Analysis. A total of 26 piglets were born from 8 recipients 
that had received embryos microinjected with the WAPPC-1 con-
struct. Screening of genomic DNA from tail biopsies using the PCR 
indicated that 7 piglets contained the transgene, for an integration 
frequency of 27%. Southern analysis of DNA from these pigs (Fig. 
2A) identifi ed only 5 positive for the transgene, including a male that 
died shortly after birth (not shown in Fig. 2A). Assuming hemizygos-
ity, female founder animals 29-2, 83-1, 83-2, and 83-3 were estimat-
ed (by PCR of serial DNA dilutions) to have 10, 20, 5, and 1 copy of 
the transgene per genome, respectively (Table 1). Two other founder 
gilts (29-1 and 83-6) appeared to be mosaic. 
Southern blot analysis of tail DNA (digested with EcoRI, which 
excises the entire WAPPC-1 transgene) from several founder pigs is 
shown in Fig. 2A. Up to three bands hybridized with the hPC cDNA 
probe (lanes 6 and 7) and were consistent with sizes of monomers, 
dimers, and trimers of the transgene. DNA from other founder ani-
mals exhibited a single band at about 9 kbp (lanes 8 and 11). South-
ern analysis of DNA from founder pig 29-2 and her offspring is 
presented in Fig. 2B; three of fi ve piglets contained the transgene.
Overall germ-line transmission of the transgene is summarized in 
Table 1. Only one of the six founder females (83-6) failed to trans-
mit the transgene. Among 53 offspring from transgenic founder ani-
mals, 28 contained the transgene, for an overall frequency of germ-
line transmission of 53%.
RNA Analysis. Northern blots of normal human liver RNA and 
mammary gland RNA from pigs 29-1, 29-2, and control were probed 
with 32P random primer-labeled hPC cDNA (Fig. 3A). Human liv-
er RNA (lanes 1, 2, 6, and 7) exhibited a single weak band at about 
1600 nucleotides (nt). A very strong band of about 1480 nt was de-
tected in RNA from pig 29-2 (lane 5) but not in RNA from the control 
pig (lane 3) or transgenic pig 29-1 (lane 4). Additional weak bands of 
approximately 2360, 2630, and 4320 nt were detected in the RNA of 
pig 29-2 (lane 5) but not in the other pig RNA samples nor the hu-
man RNA samples. Similar amounts of total RNA (from both tissue
Figure 1. Diagram of the WAPPC-1 construct. The 1.6-kbp cDNA for hPC 
[including 110 bases of poly(A)] was inserted at the Kpn I site at the fi rst 
exon of WAP, using Kpn I linker DNA. The genomic WAP gene consisted of 
2.6 kbp of 5′ fl anking promoter sequence, 3.0 kbp of coding sequence (exons 
and introns), and 1.6 kbp of 3′ fl anking DNA. Noncoding DNA segments and 
introns are indicated by dark lines. The open box is the linker DNA, the fi lled 
box is the cDNA for hPC, and stippled boxes are WAP exons. Plasmid DNA 
was isolated, digested with EcoRI, and purifi ed using HPLC to remove all 
traces of cloning vector DNA (8). Figure 2. Southern analysis of transgenic swine. DNA was isolated from tail 
biopsies of 2-day-old piglets. DNA samples were digested with EcoRI, run on 
0.7% agarose gels, transferred to nitrocellulose membranes, and hybridized 
with 32P random primer-labeled hPC cDNA. Arrows indicate sizes of DNA 
bands in kbp. (A) Founder animals. Lanes: 1-3, 250, 25, and 2.5 pg of EcoRI-
digested WAPPC-1 plasmid, respectively; 4-12, 5 μg of EcoRI-digested DNA 
from control pig and founder pigs 29-1, 29-2, 83-1, 83-2, 83-3, 83-4, 83-5, 
and 83-6, respectively. (B) Pig 29-2 and offspring. Lanes: 1–4, same as in A; 
5, founder pig 29-2; 6–10, offspring from founder animal 29-2. 
Table 1. Detection of transgenic founder animals, offspring, and rhPC expres-
sion 
                                                                     hPC antigen, μg/ml  ____
Pig       Gene copy      Germ-line       By HPC4-Mab   By polyclonal 
no.*           no.†         transmission‡           ELISA             ELISA 
_____________________________________________________________
29-1  <<1  6/9  2–3§  1–3§ 
29-2  10  4/7  10–420§  200–l000§ 
83-1  20  316  50–260§  140–650§ 
83-2  5  9/12  ND  4–8 
83-3  1  6/7  ND  ND 
83-6  <<1  0/12  0.5–1.0  2–5 
_____________________________________________________________
ND, none detected. 
* One transgenic male founder pig not included. 
† Transgene copy number estimated by PCR analysis. 
‡ Number of transgenic piglets per total number of piglets in fi rst litter. 
§ Expression levels detected over two 55 day lactations
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types) were loaded onto the gel based on 18S and 28S rRNA band in-
tensities. The hPC transcript appears to be about 100- to 1000-fold 
more intense in the RNA from transgenic pig 29-2 mammary gland 
than in RNA from human liver. 
Northern analysis using 32P random primer-labeled WAP cDNA 
as the probe (Fig. 3B) was done using the same RNA samples as 
above. Bands corresponding to about 700 nt were present in the 
mammary RNA of the control pig and transgenic pig 29-2 (lanes 3 
and 5, respectively). In addition, two very faint bands of about 2630 
and 4320 nt in size were detected in the RNA from pig 29-2 when 
probed with WAP cDNA. 
Protein Analysis. Antigen levels detected by ELISA using poly-
clonal capture ranged from 200 μg/ml to 1000 μg/ml in two lactations 
of pig 29-2 and from 140 μg/ml to 650 μg/ml in two lactations of 
pig 83-1 (Table 1). ELISA using HPC4-Mab immunocapture showed 
hPC antigen levels ranging from 10 μg/ml to 420 μg/ml and 50 μg/
ml to 260 μg/ml in transgenic pig milk from the fi rst lactations of an-
imals 29-2 and 83-1, respectively (Table 1). The antigen level de-
tected by either polyclonal or monoclonal ELISA steadily increased 
during each lactation for pig 29-2 but was relatively constant for pig 
83-1 (data not shown). The milk from four additional transgenic pigs 
exhibited hPC antigen levels ranging from none detected to 8 μg/ml 
(by polyclonal capture ELISA). Western blot analyses using WAP 
polyclonal antibody showed that no WAP antigen was produced in 
the milk of either control or transgenic pigs (data not shown). 
Purifi cation yields for successive immunosorption treatments of 
starting whey from animal 29-2 (having 1 g of hPC antigen per li-
ter) are given in Table 2. The total HPC4-Mab population capturable 
by these treatments represented 82% of the total antigen detected by 
the polyclonal ELISA. The fi rst two immunosorption steps recovered 
about 63% of the polyclonal rhPC population detected by ELISA, 
whereas the successive immunosorption at pH 8.5 recovered an addi-
tional 19%. About 15% of the polyclonal rhPC antigen was detected 
in the third immunosorbent fall-through fraction. The sum of resid-
ual hPC antigen in whey depleted by the successive HPC4-Mab im-
munosorptions and the antigen levels from each immunofraction to-
taled 97% of the antigen detected in the starting whey. Recombinant 
protein C was also purifi ed from whey taken on different days of the 
fi rst two lactations for pig 29-2 and pig 83-1. 
Coomassie blue-stained SDS/PAGE gels and Western blot anal-
ysis (using polyclonal antisera for detection) of whey and immuno-
fractionated samples from milk (animal 29-2) having 1 g of hPC an-
tigen per liter are presented in Fig. 4. The starting whey (lane 2) is 
compared to rhPC obtained by two successive immunopurifi cations 
using HPC4-Mab at pH 7.2 (lanes 3 and 4, respectively) followed by 
a third immunosorption at pH 8.5 (lane 5) and the remaining rhPC 
not immunosorbed by the HPC4-Mab (lane 6). Comparison of the 
scanning densitometries of Coomassie blue-stained SDS/PAGE gels 
(Fig. 4A) with analogous Western analysis (Fig. 4C) indicated that 
all immunocaptured products were greater than about 70% pure (Ta-
ble 2). Some degradation of whey proteins appeared to be present in 
the fi nal affi nity fall-through fraction as evident by smearing in Coo-
massie blue-stained SDS/PAGE gels under nonreducing and reduc-
ing conditions (Fig. 4 A and B). Under nonreducing conditions (Fig. 
4C), the rhPC (lanes 2–6) migrated slightly faster than hPC (lanes 1 
and 7). An apparent molecular mass of about 58 kDa was seen for 
hPC and the molecular mass of the rhPC was ≈ 55 kDa. 
The Western blot analysis using reduced conditions revealed sev-
eral differences between the rhPC and hPC. (i) The rhPC of start-
ing material (Fig. 4D, lane 2) and immunoeluates (lanes 3–5) con-
tained more single-chain material than did hPC (lanes 1 and 7). Table 
2 presents the single-chain content obtained by diffuse refl ectance 
densitometry of Western analysis from reduced SDS/PAGE. The sin-
Figure 3. Northern analysis of pig mammary tissue and human liver RNA. 
Arrows on the left indicate the positions of 18S and 28S rRNA bands (1867 
nt and 5025 nt, respectively); arrows on the right indicate the estimated 
band sizes in nt. (A) Northern blot probed with 32P random primer-labeled 
hPC cDNA. (B) Northern blot probed with 32P random primer-labeled WAP 
cDNA. Lanes: 1 and 2, 10 μg of human liver total RNA is dated from two dif-
ferent liver samples; 3–5, 10 μg each of control pig, transgenic pig 29-1, and 
transgenic pig 29-2 mammary gland total RNA, respectively; 6 and 7, repli-
cate samples of lanes 1 and 2. 
Table 2. Purifi cation of rhPC from transgenic pig whey containing 1 g of hPC antigen per liter 
_________________________________________________________________________________________________________________________
              Step                       % hPC antigen recovered*        % purity†              % single-chain content†                    Anticoagulant activity‡ units/mg _________________________________________________________________________________________________________________________
Starting whey  100 ± 5  <1  37 ± 5      ND 
Immunofraction 1  38 ± 3  >70  30 ± 5  291 ± 5 
Immunofraction 2  25 ± 5  >70  32 ± 6  107 ± 12 
Immunofraction 3  19 ± 6  >70  24 ± 4    88 ± 15 
Fall-through from eluate 3  5 ± 5  <1    3 ± 0.6      ND 
hPC reference  —   >90    3 ± 0.1  271 ± 8 _________________________________________________________________________________________________________________________
ND, not determined due to high background activity. 
* Polyclonal antigen ELISA values with standard errors from three dilutions of a single sample. 
† Calculated from densitometric comparison of Western analysis and 0.125% Coomassie-stained SDS/PAGE gels under nonreduced conditions for two replicate applications. 
‡ Standard errors as calculated from delay in AFTT for two dilutions of a single purifi cation product.
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gle-chain content was similar in the starting whey (lane 2) and the 
fi rst two immunosorption eluates (lanes 3 and 4) with about 30–37% 
single chain. However, the eluate from the HPC4-Mab immunosorp-
tion at pH 8.5 (lane 5) and the remaining fall-through fraction (lane 
6) contained less single chain—24% and 3%, respectively. hPC con-
tained only 3% single-chain species (lanes 1 and 7). (ii) The molec-
ular mass of the putative heavy-chain forms of rhPC (about 35–38 
kDa) were about 2–3 kDa lower than that of hPC (about 36–40 kDa). 
The molecular mass of the light chain of rhPC was about 18–20 kDa 
and appeared to be about 1–2 kDa lower than that of hPC. The mo-
lecular mass of the single chain of rhPC was about 55–58 kDa and 
appeared to be about 1–3 kDa lower than that of hPC. 
Table 2 presents the specifi c anticoagulant activity based upon 
delay in AFTT due to increasing amounts of normal reference plasma 
pool (NRPP), purifi ed hPC from NRPP, and rhPC obtained by suc-
cessive immunosorptions from whey (day 53, second lactation, pig 
29-2) containing 1 g of rhPC antigen per liter. The theoretical specif-
ic anticoagulant activity of hPC in NRPP is 250 units/mg by defi ni-
tion (7, 16). The specifi c anticoagulant activity of 271 ± 8 units/mg 
was determined for hPC immunopurifi ed from NRPP (Fig. 4, lanes 1 
and 7). The specifi c anticoagulant activity of rhPC from the fi rst im-
munosorption (Fig. 4, lane 3) was determined to be 291 ± 5 units/mg. 
The specifi c anticoagulant activity of rhPC from the second immu-
nosorption (Fig. 4, lane 4) was determined to be 107 ± 12 units/mg. 
The specifi c anticoagulant activity of rhPC from the immunosorption 
at pH 8.5 (Fig. 4, lane 5) was determined to be 88 ± 12 units/mg. The 
specifi c anticoagulant activity of recombinant protein C (correspond-
ing to immunofraction 1 and having a 30–60% recovery of hPC anti-
gen predicted by polyclonal ELISA) from milk obtained on different 
days of lactation from the fi rst and second lactations of pigs 29-2 and 
83-1 ranged from 70% to 150% of that obtained for hPC reference 
material (data not shown). 
DISCUSSION
Analysis of Southern blots of DNA from pig 29-2 and offspring re-
vealed different banding patterns among the piglet DNA. Upon com-
plete digestion, these bands could be reduced to a single band (data 
not shown). DNA from the offspring of pig 29-2 had different band-
ing patterns and intensities. The banding pattern of DNA from only 
one of the piglets resembled that of the parent. Transgene insertion 
into multiple chromosomes seems to have occurred for founder pig 
29-2, resulting in differing copy numbers being inherited by the off-
spring. Judging from the banding patterns and intensities observed 
for the piglet DNA, integration in sow 29-2 appears to have occurred 
on at least three chromosomes, with different copy numbers at each 
insertion site. Northern analyses (Fig. 3 A and B) showed the pres-
ence of a major transcript of about 1480 nt was detected (when hy-
bridized with the hPC cDNA probe) in the RNA of pig 29-2. In the 
human liver RNA sample, a single band of 1600 nt was detected. The 
relative amounts of hPC mRNA from pig 29-2 mammary gland and 
human liver hPC mRNA agree with the relative amounts of protein 
C produced by the two tissues. In pig 29-2 RNA, another band of 
about 2360 nt was specifi c for hPC only. Other transcripts of about 
2630 and 4320 nt (very faint) were detected in both Northern blots, 
indicating they may be read-through transcripts containing hPC and 
WAP sequences. In the present study, the mouse WAP gene was used 
to direct the expression of the hPC cDNA into the milk of transgenic 
swine, at levels that were about 1000-fold greater in transgenic pigs 
than in transgenic mice containing the same construct (8). This result 
Figure 4. SDS/PAGE and Western analysis of rhPC from the second lactation of transgenic pig 29-2. Nonreducing conditions (A and C) and reducing conditions 
(B and D) are shown for SDS/PAGE and Western blot, respectively. Whey was prepared from milk collected on day 53 of lactation. Purifi ed samples were ap-
plied with 5 μg of hPC antigen per well under nonreducing conditions (A) and 7 μg of hPC antigen per well under reducing conditions (B); starting whey and fi nal 
affi nity fall-through with ≈ 1 μg of hPC antigen and 50 μg of total protein is evident for nonreducing (A) and reducing (B) conditions. Samples analyzed by West-
ern blot were applied with 200 ng of hPC antigen per well under nonreducing conditions (C) and 300 ng of hPC antigen per well under reducing conditions (D). 
Arrows indicate positions of molecular mass standards in kDa; M, molecular mass standard mixture. Lanes: 1 and 7, American Red Cross reference hPC immu-
nopurifi ed from normal pooled donor plasma (lot no. 28309018); 2, starting whey (day 53); 3, immunofraction 1 obtained by loading starting whey at pH 7.2 us-
ing an estimated 3-fold overload of immunosorbent capacity; 4, immunofraction 2 obtained by loading of fi rst fall-through at pH 7.2 using 10% of immunosor-
bent capacity; 5, immunofraction 3 obtained by loading of second fall-through at pH 8.5 using 10% of immunosorbent capacity; 6, fi nal affi nity fall-through from 
third loading. SC, single-chain hPC forms; HC, heavy-chain hPC forms; LC, light-chain hPC forms.
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was notable because in previous studies high-level production of het-
erologous proteins in milk was achieved only in transgenic animals 
carrying either genomic (2, 17) or minigene constructs (3). Our re-
sults show that a cDNA may be used to obtain high-level expression 
of heterologous proteins in the milk of transgenic pigs.
The highest expression levels of rhPC in the milk of transgen-
ic pigs using the cDNA of hPC were similar to the expression lev-
els reported for the WAP using the intact genomic mouse WAP gene 
in transgenic pigs (2). A constant level of WAP of about 1 g/liter 
was found in milk of transgenic pigs over a 26-day lactation (17); 
rhPC (polyclonal population) increased about 2-fold during the fi rst 
26 days and >5-fold during the entire 55-day lactation of pig 29-2, 
whereas the rhPC in the milk of pig 83-1 varied about 2.5-fold. Since 
WAP and rhPC transgenic pigs contained about 10–20 copies of the 
transgene, differences in regulation may have been due to the loca-
tion of integration as well as the differences between the WAP and 
WAP-hPC gene structures.
The molecular mass of the single, heavy, and light chains of rhPC 
appeared to be similar to, but slightly lower than, those for hPC. This 
may be due to differences in carbohydrate content and structure. The 
rhPC contained a signifi cantly larger population of single-chain ma-
terial, which may indicate a rate limitation in posttranslational re-
moval of the dipeptide Lys-Arg at positions 156 to 157 (7).
The presence of different rhPC populations was also evident from 
the differences in antigen content detected by polyclonal and HPC4-
Mab ELISAs and the presence of different immunofractions obtained 
using the HPC4-Mab. The HPC4-Mab binds the activation peptide 
of hPC at pH 7.3 and thus provides a measure of the presentation of 
adomain essential for conversion of zymogen hPC to active serine 
protease form (15). Each of the immunofractions possessed different 
anticoagulant activities, but activity did not correlate well with sin-
gle-chain rhPC content. The most active fraction represented about 
38% of the hPC antigen and contained 30% single-chain material. 
This suggests that a signifi cant portion of the single-chain material 
contained in this fraction may be biologically active or that some het-
erodimeric forms are hyperactive. The lower activities of the second 
and third fractions may be a result of nonnative conformations or in-
suffi cient γ-carboxylation.
The anticoagulant activity of protein C is dependent upon proper 
γ-carboxylation of the membrane binding domain that occurs in the 
light chain (18). To determine whether γ-carboxylation had occurred 
properly in rhPC, its anticoagulant activity was assayed in vitro by 
APTT. This assay simulates coagulation in vivo by initiating clot-
ting in a mixture containing calcium, phospholipid membrane, and 
the proteins associated with hemostasis (16). As much as 38% (or 
380 μg /ml) of the porcine rhPC may be suffi ciently γ-carboxylat-
ed, as judged by the specifi c activity of immunofraction 1 by APTT 
relative to that of hPC. The transgenic pigs studied here had milk 
let down about every hour and hence the maximum rhPC secretion 
rate occurred at about 1000 μg/ml per hr. The amount of active rhPC 
secreted by the pigs (about 380 μg/ml per hr) is signifi cantly high-
er than the secretion rates of about 1 μg/ml per hr produced by hu-
man kidney 293 cell lines (7). These results provide evidence of gla 
formation not previously known to occur at high levels in mamma-
ry tissue.
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